Sartorius Stedim Biotech Acquires Majority Stake in AllPure Technologies
Sartorius Stedim Biotech's acquisition of AllPure Technologies will extends its portfolio for single-use bioprocessing.
Sartorius Stedim Biotech has signed a contract to acquire the majority stake in the US start-up, AllPure Technologies LLC. The privately owned company based in New Oxford, PA, has been in operation for four years, and earned revenue of approximately $3 million in 2013 with 25 employees. AllPure specializes in single-use components for biopharmaceutical applications, such as aseptic sampling techniques. The parties agreed not to disclose any further details of the purchase agreement.
Source: Sartorius Stedim Biotech
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
